Great free advertising for Leronlimab... Having the Philippines FDA issuing a bulletin to make more people aware of the CSP use of Leronlimab is just opening the conversation all across the medical facilities in the Philippines.

It’s to bad we can’t use this information from the CSP’s in our trial extension of CD-12. By now we should have the predicted 70 patients needed in the extension anyway but more the merrier.

The clock is ticking on trial results I believe. That would mean 28 days and a few weeks to gather the results of the CD-12 extension. We are closer than ever...

What I would like to know is what day we do or have already paused the trial? Will we pause or when will we be told? Will the trial continue after we pause for analysis or will we just use the needed 70 patients and let the trial continue as we gather the analysis? What will the FDA do for us? Let us continue even though we start the process of analysis? I have a few questions for the next webinar I guess. Unless someone has the experience of an extension and how they are used to progress trial efficacy as we are doing with CD-12. Please share if you have this knowledge.